Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study

Diabetes, Obesity & Metabolism
F Alvarez GuisasolaD Yin

Abstract

This study was undertaken to assess glycaemic control as well as changes in glycaemic control over time in patients with type 2 diabetes mellitus (T2DM) who added a sulphonylurea (SU) or thiazolidinedione (TZD) to their metformin monotherapy in typical treatment settings within seven European countries. An observational, cross-sectional multicentre study with retrospective medical chart review was conducted in Finland, France, Germany, Norway, Poland, Spain and UK. T2DM patients who added a SU or a TZD to metformin monotherapy between January 2001 and January 2006 (i.e. index date) and who had > or = 1 haemoglobin A1C (HbA1C) measurement within 12 months before the visit date, which occurred from June 2006 to February 2007, were included in the study. Demographic and clinical data were collected from medical records. The main study outcome measure was the proportion of patients with adequate glycaemic control (defined according to the International Diabetes Federation as HbA1C < 6.5%) using the most recent HbA1C measurement before the visit date. In addition, patients were grouped based upon the interval from the index date to the most recent HbA1C measurement to evaluate goal attainment and treatment changes over time. In this...Continue Reading

References

Dec 1, 1992·European Heart Journal·L E RamsayP R Jackson
Apr 1, 1985·Drug Intelligence & Clinical Pharmacy·G A Mills, J R Horn
Nov 6, 2001·Annals of Internal Medicine·L S PhillipsC S Barnes
Oct 14, 2003·Clinical Therapeutics·Thomas A Buchanan
Jan 22, 2004·JAMA : the Journal of the American Medical Association·Sharon H SaydahCatherine C Cowie
Oct 18, 2005·The American Journal of Medicine·John E Gerich
Dec 29, 2006·Diabetes Care·Zachary T Bloomgarden
Sep 25, 2007·The New England Journal of Medicine·Rury R HolmanUNKNOWN 4-T Study Group
Nov 30, 2007·The New England Journal of Medicine·Jerry Avorn

❮ Previous
Next ❯

Citations

Jun 17, 1998·Journal of the American Dietetic Association·M A MurtaughE A Reece
Apr 13, 2011·Diabetes, Obesity & Metabolism·L WatsonS Kumar
Jan 30, 2014·Primary Care Diabetes·Khalid A Al BalushiMohammed Al Za'abi
Dec 3, 2014·International Journal of Clinical Practice·S ParikhE Hardy
Jul 26, 2011·Current Medical Research and Opinion·Stephen BruntonAnthony H Barnett
Feb 26, 2016·Current Medical Research and Opinion·Louise WatsonAnthony H Barnett
May 18, 2016·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Michael Albrecht NauckHans-Juergen Woerle
Dec 21, 2017·Telemedicine Journal and E-health : the Official Journal of the American Telemedicine Association·Hang DingLeonard C Gray
Apr 11, 2015·Clinical Medicine Insights. Endocrinology and Diabetes·Andreas LieblJean-Francois Yale
Mar 14, 2019·Journal of Diabetes Science and Technology·Karel KostevStefan Pscherer
Mar 20, 2018·Scientific Reports·Vincent LefebvreChristophe Daugeron
Sep 6, 2019·Diabetes, Obesity & Metabolism·Calvin KeJuliana C N Chan
Sep 20, 2019·PharmacoEconomics Open·Judith J Gout-ZwartMaarten J Postma
Jan 23, 2013·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Salvatore CaputoUNKNOWN SOLVE Study Group
Aug 6, 2013·Diabetes, Obesity & Metabolism·J P H WildingUNKNOWN Dapagliflozin 006 Study Group
Apr 24, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Miao Yu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.